378 related articles for article (PubMed ID: 33557876)
1. What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past.
Yao Y; Liang H; Fang X; Zhang S; Xing Z; Shi L; Kuang C; Seliger B; Yang Q
J Exp Clin Cancer Res; 2021 Feb; 40(1):60. PubMed ID: 33557876
[TBL] [Abstract][Full Text] [Related]
2. Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
Röhrig UF; Reynaud A; Majjigapu SR; Vogel P; Pojer F; Zoete V
J Med Chem; 2019 Oct; 62(19):8784-8795. PubMed ID: 31525930
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Apo-Form Selective Inhibition of Indoleamine 2,3-Dioxygenase*.
Ortiz-Meoz RF; Wang L; Matico R; Rutkowska-Klute A; De la Rosa M; Bedard S; Midgett R; Strohmer K; Thomson D; Zhang C; Mebrahtu M; Guss J; Totoritis R; Consler T; Campobasso N; Taylor D; Lewis T; Weaver K; Muelbaier M; Seal J; Dunham R; Kazmierski W; Favre D; Bergamini G; Shewchuk L; Rendina A; Zhang G
Chembiochem; 2021 Feb; 22(3):516-522. PubMed ID: 32974990
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
[TBL] [Abstract][Full Text] [Related]
6. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
[TBL] [Abstract][Full Text] [Related]
7. Advances in the discovery and development of selective heme-displacing IDO1 inhibitors.
Sun L
Expert Opin Drug Discov; 2020 Oct; 15(10):1223-1232. PubMed ID: 32568559
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X
Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990
[TBL] [Abstract][Full Text] [Related]
9. Trial watch: IDO inhibitors in cancer therapy.
Le Naour J; Galluzzi L; Zitvogel L; Kroemer G; Vacchelli E
Oncoimmunology; 2020 Jun; 9(1):1777625. PubMed ID: 32934882
[TBL] [Abstract][Full Text] [Related]
10.
Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
[TBL] [Abstract][Full Text] [Related]
11. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
Prendergast GC; Malachowski WJ; Mondal A; Scherle P; Muller AJ
Int Rev Cell Mol Biol; 2018; 336():175-203. PubMed ID: 29413890
[TBL] [Abstract][Full Text] [Related]
12. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
Beatty GL; O'Dwyer PJ; Clark J; Shi JG; Bowman KJ; Scherle PA; Newton RC; Schaub R; Maleski J; Leopold L; Gajewski TF
Clin Cancer Res; 2017 Jul; 23(13):3269-3276. PubMed ID: 28053021
[No Abstract] [Full Text] [Related]
13. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
14. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
[TBL] [Abstract][Full Text] [Related]
15. Diverse chemical space of indoleamine-2,3-dioxygenase 1 (Ido1) inhibitors.
Singh R; Salunke DB
Eur J Med Chem; 2021 Feb; 211():113071. PubMed ID: 33341650
[TBL] [Abstract][Full Text] [Related]
16. A patent review of IDO1 inhibitors for cancer.
Cheong JE; Ekkati A; Sun L
Expert Opin Ther Pat; 2018 Apr; 28(4):317-330. PubMed ID: 29473428
[TBL] [Abstract][Full Text] [Related]
17. Heme-containing enzymes and inhibitors for tryptophan metabolism.
Yan D; Lin YW; Tan X
Metallomics; 2017 Sep; 9(9):1230-1240. PubMed ID: 28650043
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
Song X; Sun P; Wang J; Guo W; Wang Y; Meng LH; Liu H
Eur J Med Chem; 2020 Mar; 189():112059. PubMed ID: 31981851
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Molecular Modeling Studies of N'-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Lee DH; Lee JY; Jeong J; Kim M; Lee KW; Jang E; Ahn S; Lee CH; Hwang JY
Molecules; 2017 Nov; 22(11):. PubMed ID: 29120388
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic potential of targeting tryptophan catabolism in cancer.
Opitz CA; Somarribas Patterson LF; Mohapatra SR; Dewi DL; Sadik A; Platten M; Trump S
Br J Cancer; 2020 Jan; 122(1):30-44. PubMed ID: 31819194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]